Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]

被引：245

作者：

Lip, Gregory Y. H. ^{[1
]}

Huber, Kurt ^{[2
]}

Andreotti, Felicita ^{[3
]}

Arnesen, Harald ^{[4
]}

Airaksinen, K. Juhani ^{[5
]}

Cuisset, Thomas ^{[6
]}

Kirchhof, Paulus ^{[7
]}

Marin, Francisco ^{[8
]}

机构：

[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England

[2] Wilhelminen Hosp, Dept Med Cardiol & Emergency Med 3, Vienna, Austria

[3] A Gemelli Univ Hosp, Dept Cardiovasc Med, Rome, Italy

[4] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[5] Turku Univ Hosp, Dept Med, FIN-20520 Turku, Finland

[6] CHU Timone, Dept Cardiol, Marseille, France

[7] Univ Klinikum Munster, Dept Cardiol & Angiol, Munster, Germany

[8] Hosp Univ Virgen Arrixaca, Dept Cardiol, Murcia, Spain

来源：

THROMBOSIS AND HAEMOSTASIS | 2010年 / 103卷 / 01期

关键词：

Arial fibrillation; antithrombotic therapy; acute coronary syndrome; percutaneous coronary intervention; stenting; warfarin; ST-SEGMENT-ELEVATION; ACUTE MYOCARDIAL-INFARCTION; DUAL ANTIPLATELET THERAPY; GLYCOPROTEIN-IIB/IIIA INHIBITORS; ORAL ANTICOAGULANT-THERAPY; LONG-TERM ANTICOAGULATION; MOLECULAR-WEIGHT HEPARIN; RANDOMIZED CONTROLLED-TRIAL; RISK STRATIFICATION SCHEMA; SUPPRESS ADVERSE OUTCOMES;

D O I：

10.1160/TH09-08-0580

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.

引用

页码：13 / 28

页数：16

共 140 条

[11] The primary and secondary prevention of coronary artery disease [J].

Becker, Richard C. ;

Meade, Thomas W. ;

Berger, Peter B. ;

Ezekowitz, Michael ;

O'Connor, Christopher M. ;

Vorchheimer, David A. ;

Guyatt, Gordon H. ;

Mark, Daniel B. ;

Harrington, Robert A. .

CHEST, 2008, 133 (06) :776S-814S

[12] Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006 [J].

Bejot, Y. ;

Salem, D. Ben ;

Osseby, G. V. ;

Couvreur, G. ;

Durier, J. ;

Marie, C. ;

Cottin, Y. ;

Moreau, T. ;

Giroud, M. .

NEUROLOGY, 2009, 72 (04) :346-353

[13] Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study [J].

Bertrand, ME ;

Legrand, V ;

Boland, J ;

Fleck, E ;

Bonnier, J ;

Emmanuelson, H ;

Vrolix, M ;

Missault, L ;

Chierchia, S ;

Casaccia, M ;

Niccoli, L ;

Oto, A ;

White, C ;

Webb-Peploe, M ;

Van Belle, E ;

McFadden, EP .

CIRCULATION, 1998, 98 (16) :1597-1603

[14] Non-ST-segment elevation acute coronary syndromes: an algorithm for decision [J].

Bertrand, Michel E. ;

Collet, Jean Philippe ;

Montalescot, Gilles .

EUROPEAN HEART JOURNAL, 2008, 29 (02) :279-280

[15] Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin [J].

Beyth, RJ ;

Quinn, LM ;

Landefeld, CS .

AMERICAN JOURNAL OF MEDICINE, 1998, 105 (02) :91-99

[16] ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].

Bhatt, Deepak L. ;

Scheiman, James ;

Abraham, Neena S. ;

Antman, Elliott M. ;

Chan, Francis K. L. ;

Furberg, Curt D. ;

Johnson, David A. ;

Mahaffey, Kenneth W. ;

Quigley, Eamonn M. ;

Harrington, Robert A. ;

Bates, Eric R. ;

Bridges, Charles R. ;

Eisenberg, Mark J. ;

Ferrari, Victor A. ;

Hlatky, Mark A. ;

Kaul, Sanjay ;

Lindner, Jonathan R. ;

Moliterno, David J. ;

Mukherjee, Debabrata ;

Schofield, Richard S. ;

Rosenson, Robert S. ;

Stein, James H. ;

Weitz, Howard H. ;

Wesley, Deborah J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1502-1517

[17]

BHATT DL, TCT C 2009 SAN FRANC

[18] Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].

Boersma, E ;

Harrington, RA ;

Moliterno, DJ ;

White, H ;

Théroux, P ;

Van de Werf, F ;

de Torbal, A ;

Armstrong, PW ;

Wallentin, LC ;

Wilcox, RG ;

Simes, J ;

Califf, RM ;

Topol, EJ ;

Simoons, ML .

LANCET, 2002, 359 (9302) :189-198

[19] How does warfarin affect the activated coagulation time? [J].

Chang, RJ ;

Doherty, TM ;

Goldberg, SL .

AMERICAN HEART JOURNAL, 1998, 136 (03) :477-479

[20] Association of the arterial access site at angioplasty with transfusion and mortality: the MORTAL study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) [J].

Chase, A. J. ;

Fretz, E. B. ;

Warburton, W. P. ;

Klinke, W. P. ;

Carere, R. G. ;

Pi, D. ;

Berry, B. ;

Hilton, J. D. .

HEART, 2008, 94 (08) :1019-1025

← 1 2 3 4 5 6 7 8 9 10 →